SEARCH

SEARCH BY CITATION

References

  • 1
    Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225230.
  • 2
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 11471171.
  • 3
    Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. HEPATOLOGY 2007; 46: 3747.
  • 4
    Jacobson I. Win R study: peginterferon alfa-2b plus weight-based ribavirin improves HCV viral response compared to peginterferon alfa-2b and fixed doses of ribavirin [Abstract]. HEPATOLOGY 2005; 42( Suppl): 749A.
  • 5
    Swain M, Lai M, Shiffman ML, Cooksley W, Abergel A, Lin A, et al. Sustained virologic response resulting from treatment with peginterferon alfa-2a alone or in combination with ribavirin is durable and constitutes a cure: an ongoing 5-year follow-up [Abstract]. Gastroenterology 2007; 132: 741A.
  • 6
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. HEPATOLOGY 2007; 45: 579587.
  • 7
    Ferenci P. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 2004; 24( Suppl 2): 2531.
  • 8
    Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470477.
  • 9
    Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425433.
  • 10
    Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006; 43: 954960.
  • 11
    Marcellin P, Hadziyannis S, Berg T, Sanchez-Tapias JM, Bronowicki J, Sakai T, et al. Virologic response at 4 and 12 weeks predict high rates of sustained virologic response in genotype 1 patients treated with peginterferon alfa-2a (40 kD) and ribavirin [Abstract]. J Hepatol 2007; 46: S231S232.
  • 12
    Barbeau JM, Goforth J, Caliendo AM, Nolte FS. Performance characteristics of a quantitative TaqMan hepatitis C virus RNA analyte-specific reagent. J Clin Microbiol 2004; 42: 37393746.
  • 13
    Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 10861097.
  • 14
    Sanchez-Tapias J, Ferenci P, Diago M, Romero-Gomez M, Zeuzem S, Berg T. How can we identify HCV genotype 1 patients who may benefit from an extended treatment duration with peginterferon alfa-2a plus ribavirin [Abstract]. J Hepatol 2007; 46: S242.
  • 15
    Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451460.
  • 16
    Pearlman B, Ehleban C, Saifee S. Treatment extension to 72 weeks of pegylated interferon alfa-2b and ribavirin in hepatitis C genotype 1-infected slow responders. HEPATOLOGY 2007; 46. DOI: 10.1002/hep.21919.
  • 17
    Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. HEPATOLOGY 2004; 40: 12601265.
  • 18
    Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 26092617.
  • 19
    Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124134.
  • 20
    Buti M, Lurie Y, Blokhina N, Eteuber G, Halota W, Sumskiene J. Pegylated interferon alfa-2b plus ribavirin in patients with genotype 1 chronic hepatitis C with a slow virologic response: an early enrollers analysis of the SUCCESS study [Abstract]. HEPATOLOGY 2006; 44 ( Suppl): 342A.